Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis (Q24246447)

non-alcoholic fatty liver

inferred from title

1 reference

non-alcoholic steatohepatitis

inferred from title

1 reference

1 reference

1 reference

Francesco Angelico

1

0 references

Marco Burattin

2

0 references

Cesare Alessandri

3

0 references

Maria Del Ben

4

0 references

Flavio Lirussi

Cochrane Database of Systematic Reviews

5

0 references

publication date

24 January 2007

0 references

published in

0 references

cites work

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Metformin in the treatment of patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Treatment of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Unsuspected cirrhosis discovered during elective obesity operations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Etiopathogenesis of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Nonalcoholic fatty liver disease in the pediatric population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Association of nonalcoholic fatty liver disease with insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Non-alcoholic steatohepatitis: review of a growing medical problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

7 January 2021

inferred from DOI database lookup

Nonalcoholic steatohepatitis: an expanded clinical entity.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

7 January 2021

inferred from DOI database lookup

Contraindications to metformin therapy in patients with NIDDM

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005166.PUB2

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD005166.PUB2

1 reference

Consolidated OpenCitations Corpus – April 2017

3193931

3193931

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference